Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution
Mol Ther Oncolytics. 2023 Jul 19;30:39-55. doi: 10.1016/j.omto.2023.07.006. eCollection 2023 Sep 21.ABSTRACTOncolytic viruses, modified for tumor-restricted infection, are a promising cancer immunotherapeutic, yet much remains to be understood about factors driving their activity and outcome in the tumor microenvironment. Here, we report that oncolytic herpes simplex virus C134, previously found to exert T cell-dependent efficacy in mouse models of glioblastoma, exerts T cell-independent efficacy in mouse models of medulloblastoma, indicating this oncolytic virus uses different mechanisms in different tumors. We investigated C134's behavior in mouse medulloblastomas, using single cell RNA sequencing to map C134-induced gene expression changes across cell types, timepoints, and medulloblastoma subgroup models at whole-transcriptome resolution. Our work details substantial oncolytic virus-induced transcriptional remodeling of medulloblastoma-infiltrating immune cells, 10 subpopulations of monocytes and macrophages collectively demonstrating M1-like responses to C134, and suggests C134 be investigated as a potential new therapy for medulloblastoma.PMID:37583388 | PMC:PMC10424001 | DOI:10.1016/j.omto.2023.07.006
Source: Herpes - Category: Infectious Diseases Authors: Jack Hedberg Adam Studebaker Luke Smith Chun-Yu Chen Jesse J Westfall Maren Cam Amy Gross Ilse Hernandez-Aguirre Alexia Martin Doyeon Kim Ravi Dhital Yeaseul Kim Ryan D Roberts Timothy P Cripe Elaine R Mardis Kevin A Cassady Jeffrey Leonard Katherine E Mi Source Type: research
More News: Cancer | Cancer & Oncology | Cold Sores | Genetics | Herpes | Infectious Diseases | Medulloblastoma